issued
on 26 Dec 2023
Last Applicant/ Owned by
Windrush Court, Transport Way
Oxford
GB
OX46LT
Serial Number
97361213 filed on 13th Apr 2022
Registration Number
N/A
Correspondent Address
Roberta S. Bren
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
"SOLUTIONS"
Scientific research and development services in the field of biochemistry and genetic engineering; biochemistry engineering; genetic engineering; design of manufacturing facilities; quality control for others; scientific and technological services, namely, testing and validation services in the fields of gene and cell therapy and biotechnology; product development consultancy in the field of nanotRead More
Preparation and review of reports for regulatory approval of pharmaceuticals and bioceuticals; licensing of intellectual property; regulatory compliance consulting in the field of chemistry manufacturing and controls (CMC) activities
Medical diagnostic testing; information relating to pharmaceuticals, bioceuticals and advanced therapy medicinal products; providing medical information to medical professionals in the form of reports in the field of biotechnology, gene therapy and cell therapy; consultancy, advice and information in the field of clinical trials, healthcare, pharmaceuticals and advanced therapy medicinal products; medical advisory services relating to vaccination regimes; medical advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases, reproductive system disorders, and pharmaceutical and biochemical preparations for contraceptive purposes, in humans and animals
Scientific research and development services in the field of biochemistry and genetic engineering; biochemistry engineering; genetic engineering; design of manufacturing facilities; quality control for others; scientific and technological services, namely, testing and validation services in the fields of gene and cell therapy and biotechnology; product development consultancy in the field of nanotechnology, gene therapy and vector-based delivery systems; medical and scientific laboratory services; scientific and technological services, namely, scientific research, development and analysis in the fields of gene and cell therapy and biotechnology; industrial analysis services, namely, analysis of viral vectors and gene therapy products to assure compliance with medical and pharmaceutical industry standards; provision of scientific information in the field of biotechnology, gene therapy and cell therapy; research and scientific analysis relating to drug discovery and development for others; scientific research in the nature of conducting clinical trials for others; manufacture of viral vectors, gene therapy and cell therapy products; product and manufacturing process development in the fields of biotechnology, gene therapy and cell therapy
Custom manufacture of products relating to biotechnology; manufacture of gene therapy, and viral, retroviral, lentiviral and non-viral preparations and biopharmaceutical products; manufacture of biotechnology products; manufacture of viral and non-viral vectors; manufacture of vaccines
Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases, vaccines; pharmaceutical substances and preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by bacteria, viruses and parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; gene therapy products, namely, nanoparticles, viral vectors, retroviral vectors, lentiviral vectors and non-viral vectors for the delivery of genes to cells, all for medical purposes; vaccine manufacturing preparations; viral vaccines, namely, viral vector, retroviral vector, lentiviral vector and non-viral vector preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by bacteria, viruses and parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; biochemical and chemical products for use in medical science, namely, viral vectors; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes
No 97361213
No Service Mark
No KILB.00055.T
Yes
No
No
Yes
No
No
No
No
| Status Date | Action Taken |
|---|---|
| 26th Dec 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 31st Oct 2023 | PUBLISHED FOR OPPOSITION |
| 31st Oct 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 11th Oct 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 20th Sep 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 14th Sep 2023 | ASSIGNED TO LIE |
| 14th Sep 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 14th Sep 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 28th Apr 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 03rd Feb 2023 | NON-FINAL ACTION WRITTEN |
